Warning! This post veers away (eventually) from our focus on biosimilars. However, discussions about the Inflation Reduction Act (IRA)’s intended and unintended consequences are so prevalent, allow me to address one important point. This regards the area of pharmaceutical innovation. As inexact copies of complex biologic molecules, biosimilars would not be considered particularly innovative. The … Continue reading The IRA and Big Pharma: Is It a Real Threat to Drug Innovation?